My next podcast episode recommendation is another one on Mark Cuban's CostPlus Drug Company. Recall that my previous blog post was an interview with the CEO of that company, Alex Oshmyansky. In that episode, Dr. Oshmyansky not only revealed he was an insulin-dependent person with diabetes himself, but he also told the podcaster that Mark Cuban is surprisingly involved in seemingly miniscule details which he said was not only interesting and helpful, but also demonstrates just how involved Mr. Cuban himself is in the Cost Plus Drug Company startup itself. Also, Mr. Cuban likes to talk to the press about his new venture.
This podcast is one from This Week Health (which has several podcasts), specifically the one it calls "This Week Health: Conference" and more specifically, an episode released on April 8, 2022 entitled "Mark Cuban's Cost Plus Drugs Is Solving the Equity Problem in Prescription Medicine". It is clear Mark Cuban is not an absentee investor in the company, he really understands what's going on and has a solid plan to disrupt the costly status quo.
The drug industry is up against giant companies with lots of money and influence and complicated relationships with tentacles wrapped around government manufacturers, insurance companies, drug stores, pharmacists, retailers and more. There's all kinds of super complicated contract arrangements that include rebates and hardwired incentives that keep this giant self-licking ice cream cone stuck together. The participants in this cartel like the deals they have and they make good money on them. The system is built to keep others out.
This episode (not necessarily the whole podcast) is another one worth listening to. The link to the episode itself can be reached at https://thisweekhealth.com/captivate-podcast/mark-cubans-cost-plus-drugs-is-solving-the-equity-problem-in-prescription-medicine/.
My next podcast episode recommendation is another one on Mark Cuban's CostPlus Drug Company. Recall that my previous blog post was an interview with the CEO of that company, Alex Oshmyansky. In that episode, Dr. Oshmyansky not only revealed he was an insulin-dependent person with diabetes himself, but he also told the podcaster that Mark Cuban is surprisingly involved in seemingly miniscule details which he said was not only interesting and helpful, but also demonstrates just how involved Mr. Cuban himself is in the Cost Plus Drug Company startup itself. Also, Mr. Cuban likes to talk to the press about his new venture.
This podcast is one from This Week Health (which has several podcasts), specifically the one it calls "This Week Health: Conference" and more specifically, an episode released on April 8, 2022 entitled "Mark Cuban's Cost Plus Drugs Is Solving the Equity Problem in Prescription Medicine". It is clear Mark Cuban is not an absentee investor in the company, he really understands what's going on and has a solid plan to disrupt the costly status quo.
The drug industry is up against giant companies with lots of money and influence and complicated relationships with tentacles wrapped around government manufacturers, insurance companies, drug stores, pharmacists, retailers and more. There's all kinds of super complicated contract arrangements that include rebates and hardwired incentives that keep this giant self-licking ice cream cone stuck together. The participants in this cartel like the deals they have and they make good money on them. The system is built to keep others out.
This episode (not necessarily the whole podcast) is another one worth listening to. The link to the episode itself can be reached at https://thisweekhealth.com/captivate-podcast/mark-cubans-cost-plus-drugs-is-solving-the-equity-problem-in-prescription-medicine/.
No comments:
Post a Comment
Every comment is moderated. Comments with links to commercial web sites (or profiles) to improve SEO ratings are deleted and flagged as spam to Google, so you won't improve your SEO ratings, you'll damage them. Save your energy (and mine) by not bothering to post fake comments here. I reserve the right to post comments with links and profiles removed.